Abstract：
Pharmacokinetics studies have investigated meloxicam, a non-steroidal anti-inflammatory drug, dosing strategies in a wide variety of non-domestic animals; however, there is no prior study examining well-founded dosing for pinnipeds. To develop dosing protocols, pharmacokinetic information is needed, with an examination of differences between pinniped species. Apparently, healthy California sea lions (Zalophus californianus: CSL; n = 13) and Pacific harbor seals (Phoca vitulina richardii: PHS; n = 17) that had completed rehabilitation were enrolled into a population-based pharmacokinetic study. Each animal was administered a single oral dose of meloxicam at 0.1 mg/kg, and two blood samples were collected from each animal at varying intervals during a 96-h study period. Plasma concentrations of meloxicam were determined by high-pressure liquid chromatography. Data were analyzed with nonlinear mixed effects modeling (Phoenix® NLME™, Certara, St. Louis, MO 63105, USA). The results indicated that in PHS, peak plasma concentration (Cmax) was 0.33 μg/mL with an elimination half-life (Ke t½) of 31.53 h. In CSL, Cmax was 0.17 μg/mL with Ke t½ of 32.71 h. All animals enrolled completed the study without outward adverse clinical signs. The elimination half-life was longer than previously recommended dosing intervals for pinnipeds; however, we cannot speculate in the optimum clinical dose from these results.
摘要：
药代动力学研究已经调查了美洛昔康，一种非甾体抗炎药,各种非家养动物的给药策略；然而，先前没有研究检查有充分依据的in足动物给药。为了制定给药方案，需要药代动力学信息，研究了尖顶物种之间的差异。显然,已完成康复的健康加利福尼亚海狮(Zalophuscalifornianus:CSL;n=13)和太平洋海豹(Phocavitulinarichardii:PHS;n=17)被纳入一项基于人群的药代动力学研究.每只动物以0.1mg/kg的剂量口服美洛昔康，在96小时的研究期间，以不同的间隔从每只动物收集两份血液样本。美洛昔康的血浆浓度通过高压液相色谱法测定。采用非线性混合效应模型分析数据(Phoenix®NLME™，Certara,圣路易斯,MO63105，美国）。结果表明，在PHS中，峰值血浆浓度（Cmax）为0.33μg/mL，消除半衰期（Ket½）为31.53h。在CSL中，Cmax为0.17μg/mL,Ket1/2为32.71小时。所有登记的动物完成了研究,没有向外的不良临床体征。消除半衰期比以前推荐的pin足动物给药间隔更长；但是，我们无法从这些结果推测最佳临床剂量.
